See more : Global Net Lease, Inc. (GNL-PE) Income Statement Analysis – Financial Results
Complete financial analysis of Telomir Pharmaceuticals, Inc. Common Stock (TELO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Telomir Pharmaceuticals, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Yellow Corporation (YELL) Income Statement Analysis – Financial Results
- H. Lundbeck A/S (LUN.CO) Income Statement Analysis – Financial Results
- Eurohold Bulgaria AD (EHG.WA) Income Statement Analysis – Financial Results
- Almonty Industries Inc. (AII.TO) Income Statement Analysis – Financial Results
- Delta-Fly Pharma, Inc. (4598.T) Income Statement Analysis – Financial Results
Telomir Pharmaceuticals, Inc. Common Stock (TELO)
About Telomir Pharmaceuticals, Inc. Common Stock
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.94M | 0.00 | 0.00 |
| Gross Profit | -3.94M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.57M | 833.21K | 126.49K |
| General & Administrative | 600.19K | 20.94K | 11.64K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 600.19K | 20.94K | 11.64K |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.94M | 854.15K | 138.13K |
| Cost & Expenses | 3.94M | 854.15K | 138.13K |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.64M | 0.00 | 0.00 |
| Depreciation & Amortization | -7.49M | 854.15K | 138.13K |
| EBITDA | -11.43M | -854.15K | -138.13K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.94M | -854.15K | -138.13K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -9.13M | 0.00 | 0.00 |
| Income Before Tax | -13.07M | -854.15K | -138.13K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -854.14K | -138.13K |
| Net Income | -13.07M | -854.15K | -138.13K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -0.44 | -0.03 | 0.00 |
| EPS Diluted | -0.44 | -0.03 | 0.00 |
| Weighted Avg Shares Out | 29.61M | 29.61M | 29.61M |
| Weighted Avg Shares Out (Dil) | 29.61M | 29.61M | 29.61M |
Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?
On Tuesday, Telomir Pharmaceuticals, Inc. TELO revealed preclinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several key parameters of Type 2 diabetes mellitus.
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
MIAMI, FL / ACCESSWIRE / November 21, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of Telomir-1, a compound designed to effectively turn back...
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday
Interview to Air Sunday, September 29, 2024 at 5:30 PM EST on Fox Business Network MIAMI, FL / ACCESSWIRE / September 26, 2024 / Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company seeking to lead developments in...
Telo Genomics Assessing MRD Status in TELO-DMRD Study
Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is...
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications
MIAMI, FL / ACCESSWIRE / September 4, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, is pleased to announce the appointment of...
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
Promising results with Telomir-1 Demonstrates Potential in Promoting Life Quality and Longevity in Senior Dogs TAMPA, FL / ACCESSWIRE / August 20, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage company seeking to lead developments in...
Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman
Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”),...
Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes
TAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA's protective...
Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel
Drug Information Association (DIA) 2024 is the largest global, multidisciplinary event for the professionals involved in the discovery, development, and lifecycle management of pharmaceuticals, biotechnology, medical devices, and related products Drug Information Association (DIA) 2024 is the largest global, multidisciplinary...
Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1
Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines
Source: https://incomestatements.info
Category: Stock Reports